Advisory Services Network, LLC Anavex Life Sciences Corp. Transaction History

Advisory Services Network, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$5.04 - $9.95 $15,775 - $31,143	3,130 New	3,130 $29,000
Q1 2023 May 17, 2023	SELL	$8.32 - $11.75 $832 - $1,175	-100 Reduced 2.02%	4,850 $41,000
Q4 2022 Feb 13, 2023	BUY	$7.65 - $14.43 $37,867 - $71,428	4,950 New	4,950 $45,000
Q3 2021 Nov 05, 2021	SELL	$16.82 - $25.75 $95,874 - $146,775	-5,700 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$10.16 - $28.86 $57,912 - $164,502	5,700 New	5,700 $130,000
Q1 2021 May 24, 2021	SELL	$5.17 - $16.13 $28,435 - $88,715	-5,500 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.8 - $5.0 $20,900 - $27,500	5,500 New	5,500 $25,000
Q2 2020 Aug 10, 2020	SELL	$2.62 - $5.2 $13,100 - $26,000	-5,000 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.38 - $5.81 $11,900 - $29,049	5,000 New	5,000 $16,000
Q1 2019 May 20, 2019	SELL	$1.68 - $3.42 $2,520 - $5,130	-1,500 Closed	0 $0
Q2 2018 Jul 27, 2018	BUY	$2.08 - $4.26 $3,120 - $6,390	1,500 New	1,500 $4,000
Q4 2017 Feb 08, 2018	SELL	$3.12 - $4.94 $1,416 - $2,242	-454 Closed	0 $0
Q2 2017 Aug 17, 2017	BUY	N/A	454	454 $2,000

157

27.4M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $875M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Advisory Services Network, LLC, based on Form 13F filings with the SEC.

Stay updated on Advisory Services Network, LLC with notifications on news.